Core Viewpoint - Qilu Pharmaceutical's Bevacizumab injection (brand name: Ankevda) has received marketing approval from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of various malignancies, marking a significant entry into the high-end market for Chinese biopharmaceuticals [1][3]. Group 1: Product Approval and Market Impact - The approval of Bevacizumab signifies the recognition of high-quality Chinese biopharmaceuticals on a global scale, benefiting more patients [3]. - Bevacizumab is the first anti-tumor angiogenesis monoclonal antibody globally and is recommended as a first-line standard treatment for several cancers, including non-small cell lung cancer and colorectal cancer [3]. - The drug operates through three main mechanisms: regression of existing blood vessels, inhibition of new blood vessel formation, and anti-vascular permeability [3]. Group 2: Clinical and Economic Benefits - Since its launch in December 2019, Qilu's Bevacizumab has significantly reduced the economic burden on patients and has benefited over one million cancer patients [3][5]. - The drug's affordability is crucial for increasing accessibility for late-stage cancer patients in the UK, where treatment options are limited due to high costs [3]. Group 3: Company Strategy and Global Expansion - Qilu Pharmaceutical is accelerating its international expansion, with plans to launch Bevacizumab in the UK in early 2024 to meet unmet clinical needs [3][5]. - The company has received approvals for 27 formulation products in the EU/UK and has exported 19 formulations, with a projected 32.5% year-on-year growth in exports to Europe by 2025 [7]. - Qilu is the only domestic company exporting formulations to major regulatory markets, including the EU, US, UK, Japan, Australia, and Canada, with its products reaching 110 countries and benefiting approximately 1.5 billion people annually [7].